After the traditional anti-arthritic drug rofecoxib was found to have side effects of increasing the risk of thrombosis, the cardiovascular safety of another traditional painkiller, Voltaren (diclofenac), was also questioned. As a non-steroidal anti-inflammatory drug (NSAIDs), there have been no clinical trials to verify its side effects.
Voltaren is the most common painkiller in many countries around the world and is also an over-the-counter drug in many places. Drugs may have side effects that pose a significant health hazard to the public. Therefore, the European Medicines Agency (EMA) recently led a data of 6.3 million Danish adults led by Morten Schmidt of Aarhus University. Investigate experiments.
In Denmark, most NSAIDs require a prescription to purchase. Therefore, the Danish National Health Service can collect information on all NSAIDs users through the grant distribution record. At the same time, the researchers also screened a group of people who met the conditions of the survey from the patient registration information of the national hospital. From 1996 to the present, after the study removed patients with a history of heart disease and other major illnesses, a total of 6.3 million patients who continued to take NSAIDs for more than one year were included in the database.
The researchers found that even after controlling for other potential influencing factors, taking Voltaren would increase cardiovascular disease within 30 days compared to other traditional NSAIDs such as ibuprofen, naproxen, or paracetamol (Bai Yunning). Probability, including arrhythmia, palpitations, ischemic MI, heart failure, and heart attack. The occurrence of side effects has nothing to do with gender, age, and dose.
Voltaren users have a higher probability of cardiogenic death than those who do not take NSAIDs. In addition, users of Voltaren have a higher risk of bleeding in the upper digestive system than users of ibuprofen and naproxen. The authors also point out that although Voltaren increases the probability of cardiovascular disease, these side effects are lower for individual users.
Although this is an observational study, there are no conditions for strict control of variables in the laboratory, but its data size and random extraction mechanism make the experimental results have strong clinical guidance. Data sources obtained through state aid records prevent statistical biases, and data on the actual distribution of drugs in conjunction with pharmacies are more predictive of real drug use than prescription data.
The researchers concluded by: “Voltaren has clinical value in relieving pain and inflammation, but given its cardiovascular and digestive side effects, we should give priority to other traditional NSAIDs in the clinic.” Call for the inclusion of Voltaren in the category of prescription drugs worldwide to prevent patient abuse. At the same time, Voltaren’s drug packaging box should also indicate its potential side effects, so that patients have full right to know.